Diabetic neuropathies and wound healing therapeutic - Immunor AS
Latest Information Update: 01 Mar 2024
At a glance
- Originator Immunor AS
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Diabetic neuropathies
Most Recent Events
- 20 Feb 2024 Investigation in Diabetic neuropathies in Norway (unspecified route) (Immunor AS pipeline, February 2024)